Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acumen Pharmaceuticals Inc
(NQ:
ABOS
)
2.340
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
2.340
Bid (Size)
2.200 (1)
Ask (Size)
2.410 (20)
Prev. Close
2.340
Today's Range
2.340 - 2.340
52wk Range
1.810 - 11.31
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
Performance
YTD
-55.51%
-55.51%
1 Month
+6.12%
+6.12%
3 Month
-62.50%
-62.50%
6 Month
-58.29%
-58.29%
1 Year
-62.97%
-62.97%
More News
Read More
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals's Earnings Outlook
November 10, 2023
Via
Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
August 07, 2023
Via
Benzinga
Earnings Scheduled For November 13, 2023
November 13, 2023
Via
Benzinga
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Via
InvestorPlace
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 07, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
November 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
October 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
October 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
September 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Via
Benzinga
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
August 01, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
Via
News Direct
Exposures
Product Safety
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
July 26, 2023
Via
Benzinga
MarketBeat Week in Review – 7/17 - 7/21
July 22, 2023
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
July 19, 2023
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Acumen Announces Pricing of Upsized $130 Million Public Offering
July 18, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.